Skip to main content

Branded

  • Biogen names McKenzie EVP pharmaceutical operations, technology

    CAMBRIDGE, Mass. — Biogen on Thursday announced named Paul McKenzie as its EVP pharmaceutical operations and technology, effective July 1.  McKenzie, who was previously the company’s SVP global biologics manufacturing and technical operations, will head the company’s asset management, technical development, supply chain operations, global manufacturing, quality and engineering. 
     

  • Study: Diabetes drug treats liver disease in Type 2, prediabetes patients

    PHILADELPHIA — A new study whose results were published online in the Annals of Internal Medicine has found promise for the treatment of the fatty liver disease nonalcoholic steatohepatitis (NASH) in patients with prediabetes and Type 2 diabetes. NASH currently has no FDA-approved treatment. 
     

  • Investment firm Snow Phipps acquires ECRM

    BOSTON – BV Investment Partners on Thursday announced the sale of ECRM, an integrated services, software and data provider serving consumer product manufacturers and retailers, to Snow Phipps Group.

    Financial terms were not disclosed.

  • Pro-generics access bill gets Senate subcommittee hearing

    WASHINGTON — The Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights on Tuesday held a hearing on the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, a piece of legislation that was introduced last week that could increase patient access to generics if passed. 
     

  • Taro CFO departs

    HAWTHORNE, N.Y. — Taro Pharmaceuticals announced late Tuesday that its CFO, Michael Kalb, had resigned his position to become CFO at another publicly traded company, effective June 29. Taro noted that Kalb’s departure was not the result of a dispute or disagreement with the company, including anything having to do with its accounting practices or financial reporting. 
     

  • FDA approves Opko’s Rayaldee

    SILVER SPRING, Md. — The Food and Drug Administration has approved Opko Health’s Rayaldee (calcifediol) extended-release capsules, the company announced Tuesday. The drug is indicated to treat secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease and a serum total 25-hydroxyvitamin D level of less than 30 ng/mL. 
     

  • Research: Pharmacy-driven flu shots boost vaccination rates among millennials

    PHILADELPHIA - The availability of influenza vaccinations at the neighborhood pharmacy has boosted vaccination rates among millennials, according to research recently published in the American Journal of Public Health.

    The authors found that increased adoption rates followed states allowing pharmacists to administer the vaccine.

  • NACDS, NCPA express support for a TRICARE acquisition cost parity pilot program

    WASHINGTON – The National Association of Chain Drug Stores and the National Community Pharmacists Association on Wednesday urged adoption of a key TRICARE provision when House of Representatives and Senate negotiators work to reconcile differences in the House and Senate versions of the FY2017 National Defense Authorization Act.

X
This ad will auto-close in 10 seconds